Pharmaceuticals - Turkey

  • Turkey
  • In 2024, the projected revenue in the Pharmaceuticals market in Turkey is expected to reach US$2,094.00m.
  • Among the various markets, the largest one is Oncology Drugs, with a projected market volume of US$326.50m in 2024.
  • Looking ahead, the revenue is anticipated to exhibit an annual growth rate of 3.86% (CAGR 2024-2029), resulting in a market volume of US$2,530.00m by 2029.
  • When compared globally, United States is expected to generate the highest revenue in the Pharmaceuticals market, with an estimated amount of US$630.30bn in 2024.
  • Turkey's pharmaceutical market is experiencing a surge in demand for generic drugs due to their affordability and availability.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Turkey has been experiencing significant growth in recent years, driven by various factors that are unique to the country.

Customer preferences:
Turkey has a large and growing population, with an increasing demand for healthcare services and products. The country has a universal healthcare system that provides free or low-cost healthcare to all citizens. However, many people still prefer to use private healthcare services, which has led to a growing demand for pharmaceutical products. In addition, there is a growing trend towards self-medication, with many people choosing to purchase over-the-counter drugs for minor ailments.

Trends in the market:
One of the key trends in the Turkish pharmaceuticals market is the increasing focus on research and development. Many local companies are investing heavily in R&D to develop new drugs and treatments, while multinational companies are also expanding their operations in the country. Another trend is the growing demand for generic drugs, which are cheaper than branded products and are becoming increasingly popular among consumers. Finally, there is a trend towards consolidation in the market, with many smaller companies being acquired by larger players.

Local special circumstances:
One of the unique factors that is driving growth in the Turkish pharmaceuticals market is the country's strategic location. Turkey is situated at the crossroads of Europe and Asia, making it an important hub for pharmaceutical companies looking to expand their operations in these regions. In addition, the Turkish government has implemented a number of policies aimed at promoting the development of the local pharmaceutical industry, including tax incentives and subsidies for R&D.

Underlying macroeconomic factors:
The Turkish economy has been growing steadily in recent years, with a strong focus on exports and foreign investment. This has led to increased demand for healthcare services and products, including pharmaceuticals. In addition, the country's large and growing population, coupled with a growing middle class, has created a significant market for pharmaceutical companies. Finally, the Turkish government's focus on healthcare reform and investment in the sector is also driving growth in the pharmaceuticals market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)